The company entered into an agreement with Novo Nordisk India Pvt Ltd ... at Philippines and Sri Lanka for a total consideration costing Rs. 2000 Crores. Accordingly, Curatio Health Care (I ...

James Manning / PA Images / Getty Images After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...

In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...

Novo Nordisk (NVO) reported mixed earnings for the third quarter of 2024 but beat Wall Street revenue expectations for its blockbuster weight-loss drug, Wegovy. Novo announced an earnings per ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in ...

MILAN, Nov 7 (Reuters) - Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tab shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as underwhelming guidance ...

Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide By Robin Foster HealthDay Reporter THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

MILAN (Reuters) - Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as underwhelming guidance for next year overshadowed strong ...

1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...